Review Voucher Program For Rare Pediatric Diseases Should Not Be Reauthorized, US FDA Says
This article was originally published in SRA
More time is needed to gauge whether the US Food and Drug Administration's rare pediatric disease priority review voucher program has actually encouraged the development of new treatments, the Government Accountability Office believes. The FDA, however, isn't interested in giving the incentive program any more time to try to prove itself.
Register for our free email digests: